Show Search Form

Search Results

human indexable	true false
published	true false
registered interest	true false
answer date	exactly: or between: and
date	exactly: or between: and
date tabled	exactly: or between: and
answering body
question status
answering dept id
answering dept short name
answering dept sort name
ddp created
ddp modified
hansard heading
house id
identifier
legislature	pref label
parliament number
question first answered
question text
session
session number
tabling member printed
title
type
uin
version
written parliamentary question type
answer	is ministerial correction true false answer text question first answered
creator	label
publisher	pref label
tabling member	label

Search

753958

	human indexable
	published
	registered interest
	answer date	02/08/2017
	date	19/07/2017
	date tabled	19/07/2017
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	ddp created	19/07/2017 22:26:10 19/07/2017 22:26:10
	ddp modified	19/07/2017 22:26:10 31/07/2017 14:11:05
	hansard heading	Radioisotopes: Imports
	house id	2
	identifier	HL1104
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	31/07/2017 13:38:56
	question text	Her Majesty's Government (1) what assessment they have made of the potential impact of not reaching agreement with the EU by April 2019 on the supply of the radioisotope molybdenum-99 used to produce technetium-99m which is required for over 80 per cent of diagnostic medicine procedures in the UK; (2) what assessment they have made of the potential impact of delays or disruption to the supply of diagnostic medicine procedures that may result; and (3) what contingency plans they have put in place to mitigate such delays or disruption to that supply after Brexit.
	session	2017/19
	session number	1
	tabling member printed	Lord Mendelsohn
	title	House of Lords Tabled Parliamentary Question 2017/19 HL1104
	type	WrittenParliamentaryQuestion
	uin	HL1104
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction answer text <p>The Government is fully aware of the importance of molybdenum-99 and the reliance on this medical radioisotope for diagnostic procedures in the National Health Service. The United Kingdom’s ability to import medical isotopes from Europe and the rest of the world will not be affected by withdrawal from Euratom. It is in everyone’s interest to not disrupt the timely access of treatment to patients and to ensure that cross-border trade with the European Union and Euratom is as frictionless as possible.</p> question first answered 31/07/2017 13:38:56
	creator	4286 label Biography information for Lord Mendelsohn
	publisher	25277 pref label House of Lords
	tabling member	4286 label Biography information for Lord Mendelsohn

753959

	human indexable
	published
	registered interest
	answer date	02/08/2017
	date	19/07/2017
	date tabled	19/07/2017
	ddp created	19/07/2017 22:26:11
	answering body	Department for Exiting the European Union
	question status	Tabled
	answering dept id	203
	answering dept short name	Exiting the European Union
	answering dept sort name	Exiting the European Union
	ddp modified	19/07/2017 22:26:11 02/08/2017 15:11:02
	hansard heading	Radioisotopes: Imports
	house id	2
	identifier	HL1105
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	02/08/2017 14:39:06
	question text	Her Majesty's Government what terms they are seeking to agree with the European Union to ensure that no additional delays or restrictions are placed on imports of molybdenum-99 to the UK following the UK's departure from Euratom.
	session	2017/19
	session number	1
	tabling member printed	Lord Mendelsohn
	title	House of Lords Tabled Parliamentary Question 2017/19 HL1105
	type	WrittenParliamentaryQuestion
	uin	HL1105
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction answer text <p>The UK’s ability to import medical isotopes from Europe and the rest of the world will not be affected by withdrawal from Euratom.</p><p>The import or export of medical radioisotopes, including molybdenum-99 is not subject to any Euratom licensing requirements.These isotopes are governed and regulated under the Euratom framework; however, Euratom places no restrictions on the export of medical isotopes to countries outside the EU.</p><p>It is in everyone’s interest to not disrupt the timely access of treatment to patients; and to ensure that cross-border trade with the EU and Euratom is as frictionless as possible.</p><p> </p> question first answered 02/08/2017 14:39:06
	creator	4286 label Biography information for Lord Mendelsohn
	publisher	25277 pref label House of Lords
	tabling member	4286 label Biography information for Lord Mendelsohn

993365

	human indexable
	published
	registered interest
	answer date	05/11/2018
	date	22/10/2018
	date tabled	22/10/2018
	ddp created	22/10/2018 21:35:09
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	22/10/2018 21:45:14 05/11/2018 15:00:03
	hansard heading	Haematological Cancer: Drugs
	house id	2
	identifier	HL10893
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	05/11/2018 14:29:39
	question text	To ask Her Majesty's Government (1) how many drugs were available on the NHS for the treatment of blood cancer, and (2) how much the NHS spent on blood cancer drugs, in each of the past five years.
	session	2017/19
	session number	1
	tabling member printed	Lord Mendelsohn
	title	House of Lords Tabled Parliamentary Question 2017/19 HL10893
	type	WrittenParliamentaryQuestion
	uin	HL10893
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction answer text <p>NHS England has advised that it is not possible to provide a comprehensive list of drugs that are available specifically for blood cancer or how much the National Health Service spends on blood cancer drugs as cancer drugs are often licenced for multiple different types of cancer.</p> question first answered 05/11/2018 14:29:39
	creator	4286 label Biography information for Lord Mendelsohn
	publisher	25277 pref label House of Lords
	tabling member	4286 label Biography information for Lord Mendelsohn

922991

	human indexable
	published
	registered interest
	answer date	26/06/2018
	date	12/06/2018
	date tabled	12/06/2018
	ddp created	12/06/2018 21:25:53
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	12/06/2018 21:35:49 26/06/2018 12:46:04
	hansard heading	Leukaemia: Ibrutinib
	house id	2
	identifier	HL8564
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	26/06/2018 12:13:53
	question text	To ask Her Majesty's Government (1) what evidence NHS England considered, (2) which clinicians it consulted, and (3) which patient groups it consulted when deciding that ibrutinib should not be prescribed to people with chronic lymphocytic leukaemia who have been in remission for more than three years.
	session	2017/19
	session number	1
	tabling member printed	Lord Mendelsohn
	title	House of Lords Tabled Parliamentary Question 2017/19 HL8564
	type	WrittenParliamentaryQuestion
	uin	HL8564
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction answer text <p>NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>In the case of NICE Technology Appraisal TA429 for ibrutinib in previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation, NICE issued the following statement on 8 June 2018:</p><p><strong> </strong>“Given the evidence that was considered by the NICE appraisal committee, we consider it reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment. Because unsuitability for retreatment is not defined in the guidance, we consider it appropriate for NHS England, as the commissioner, to take clinical advice in order to do so.”</p><p>NHS England took clinical advice in setting the specific treatment criteria linked to this appraisal and we are advised that the criteria were derived from the main study that had underpinned the NICE guidance and are consistent with guidance issued by the European Society for Medical Oncology last updated in June 2017. Between January 2017 and May 2018, nearly 1,000 patients were registered to receive treatment with ibrutinib in this indication. This is in line with NICE’s estimates that 700 adults per year would be eligible for treatment as a result of its guidance.</p><p>However, NHS England has further advised that it is more than willing to receive and review by the end of July, any further evidence that patients and clinicians wish to submit on this matter. The evidence will first be considered by NHS England’s Chemotherapy CRG, with advice and recommendations from this group then being submitted to the National Medical Director, Professor Steve Powis, for consideration.</p><p>During 2017/18, 1,193 Individual Funding Requests were considered by NHS England. An analysis of how may related to treatments for blood cancer has not been conducted.</p><p> </p> question first answered 26/06/2018 12:13:53
	creator	4286 label Biography information for Lord Mendelsohn
	publisher	25277 pref label House of Lords
	tabling member	4286 label Biography information for Lord Mendelsohn

885902

	human indexable
	published
	registered interest
	answer date	01/05/2018
	date	17/04/2018
	date tabled	17/04/2018
	ddp created	17/04/2018 20:45:16
	answering body	Department for Business, Energy and Industrial Strategy
	question status	Tabled
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	ddp modified	17/04/2018 20:56:04 30/04/2018 17:10:02
	hansard heading	Artificial Intelligence
	house id	2
	identifier	HL6996
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	30/04/2018 16:38:54
	question text	To ask Her Majesty's Government by what metrics they will determine whether the UK has become “the go-to destination for AI innovation and investment”, as set out in their Industrial Strategy White Paper; and by what date they intend to achieve that aim.
	session	2017/19
	session number	1
	tabling member printed	Lord Mendelsohn
	title	House of Lords Tabled Parliamentary Question 2017/19 HL6996
	type	WrittenParliamentaryQuestion
	uin	HL6996
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction answer text <p>AI is emerging in its own right as a nascent industry with the potential to raise the productivity of diverse sectors and create entirely new jobs. To maximise this potential, the recently announced AI Sector Deal will establish a new AI Council to bring together respected leaders in the field from across academia and industry; a new delivery body within the government – the Office for Artificial Intelligence – to support it; and a new Centre for Data Ethics and Innovation.</p><p> </p><p>Oversight of the implementation of the Sector Deal will be led by the Office for Artificial Intelligence, which will review progress against objectives regularly.</p><p> </p><p>The new government Office for Artificial Intelligence will be established with responsibility for implementing this Sector Deal. It will support the AI Council which will oversee and drive the implementation of the deal.</p><p> </p><p>An early role for the Office for AI will be to agree implementation plans for each section of the deal, including agreed success metrics.</p><p> </p><p>Membership of the AI Council will be announced ahead of the first meeting. The main aim of the AI Council will be to provide strategic leadership and momentum in delivery.</p><p> </p><p>The Office for AI will report to the AI Council regularly and will be subject to challenge sessions from government ministers on progress in implementing the Sector Deal. The Industrial Strategy team will provide the challenge on delivery timetable, metrics and ambition on outcomes as well as providing updates and escalation to ministers across the suite of Sector Deals.</p> question first answered 30/04/2018 16:38:54
	creator	4286 label Biography information for Lord Mendelsohn
	publisher	25277 pref label House of Lords
	tabling member	4286 label Biography information for Lord Mendelsohn

1005628

	human indexable
	published
	registered interest
	answer date	26/11/2018
	date	12/11/2018
	date tabled	12/11/2018
	ddp created	12/11/2018 22:05:50
	answering body	Department for Business, Energy and Industrial Strategy
	question status	Tabled
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	ddp modified	12/11/2018 22:16:52 19/11/2018 16:15:13
	hansard heading	Companies: Codes of Practice
	house id	2
	identifier	HL11399
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	19/11/2018 15:43:10
	question text	To ask Her Majesty's Government by what process and criteria they will evaluate companies’ explanations for non-compliance with the revised UK Corporate Governance Code of July 2018; and what steps they plan to take when they deem explanations for non-compliances not to be satisfactory.
	session	2017/19
	session number	1
	tabling member printed	Lord Mendelsohn
	title	House of Lords Tabled Parliamentary Question 2017/19 HL11399
	type	WrittenParliamentaryQuestion
	uin	HL11399
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction answer text <p>The UK Corporate Governance Code is the responsibility of the Financial Reporting Council. It is the responsibility of investors to assess the quality of reporting and engage with companies accordingly.</p><p> </p><p>The 2018 Code is a substantial revision and comes into force for accounting periods beginning on or after 1 January 2019. Reporting against the revised Code will therefore not be required until 2020 when companies publish their annual reports and accounts for the preceding year. However, the FRC intends to evaluate the extent of early adoption of the new Code in terms of reporting on the application of its Principles and compliance or otherwise with its Provisions and to publish its findings at the end of 2019.</p><p> </p><p>The FRC is the subject of an independent review being led by Sir John Kingman which is expected to report before the end of the year.</p><p> </p> question first answered 19/11/2018 15:43:10
	creator	4286 label Biography information for Lord Mendelsohn
	publisher	25277 pref label House of Lords
	tabling member	4286 label Biography information for Lord Mendelsohn

788337

	human indexable
	published
	registered interest
	answer date	27/11/2017
	date	13/11/2017
	date tabled	13/11/2017
	ddp created	13/11/2017 22:49:04
	answering body	Department for Business, Energy and Industrial Strategy
	question status	Tabled
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	ddp modified	13/11/2017 22:57:00 20/11/2017 15:49:02
	hansard heading	Small Businesses: Complaints
	house id	2
	identifier	HL3129
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	20/11/2017 15:17:54
	question text	To ask Her Majesty's Government further to the Written Answer by Lord Henley on 10 November (HL2702), how many complaints from small businesses have been received by (1) the Department for Business, Energy and Industrial Strategy, and (2) the Small Business Commissioner's office, since 1 October; and of those, how many have not been accepted because of the delay in the launch of the Small Business Commissioner's complaints handling service.
	session	2017/19
	session number	1
	tabling member printed	Lord Mendelsohn
	title	House of Lords Tabled Parliamentary Question 2017/19 HL3129
	type	WrittenParliamentaryQuestion
	uin	HL3129
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction answer text <p>Since 1 October, the Department for Business Energy &amp; Industrial Strategy has not received any complaints from small businesses that would be in scope of the proposed Small Business Commissioner’s complaints handling service. The office of the Small Business Commissioner has received two enquiries on behalf of small businesses, neither of which would be in scope of the proposed complaints handling service. Secondary legislation relating to this complaints handling service is currently before this House, and would need to come into force before the complaints service could launch. Subject to the will of Parliament, when it is in force small businesses will be able to submit complaints for consideration, including complaints relating to the period from 6 April 2017.</p> question first answered 20/11/2017 15:17:54
	creator	4286 label Biography information for Lord Mendelsohn
	publisher	25277 pref label House of Lords
	tabling member	4286 label Biography information for Lord Mendelsohn

922989

	human indexable
	published
	registered interest
	answer date	26/06/2018
	date	12/06/2018
	date tabled	12/06/2018
	ddp created	12/06/2018 21:25:51
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	12/06/2018 21:35:45 26/06/2018 12:46:06
	hansard heading	NHS: Drugs
	house id	2
	identifier	HL8562
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	26/06/2018 12:13:53
	question text	To ask Her Majesty's Government how NHS England formulates approval criteria for drugs already approved by the National Institute for Health and Clinical Excellence; and how it involves (1) patients, and (2) clinicians in this process.
	session	2017/19
	session number	1
	tabling member printed	Lord Mendelsohn
	title	House of Lords Tabled Parliamentary Question 2017/19 HL8562
	type	WrittenParliamentaryQuestion
	uin	HL8562
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction answer text <p>NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>In the case of NICE Technology Appraisal TA429 for ibrutinib in previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation, NICE issued the following statement on 8 June 2018:</p><p><strong> </strong>“Given the evidence that was considered by the NICE appraisal committee, we consider it reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment. Because unsuitability for retreatment is not defined in the guidance, we consider it appropriate for NHS England, as the commissioner, to take clinical advice in order to do so.”</p><p>NHS England took clinical advice in setting the specific treatment criteria linked to this appraisal and we are advised that the criteria were derived from the main study that had underpinned the NICE guidance and are consistent with guidance issued by the European Society for Medical Oncology last updated in June 2017. Between January 2017 and May 2018, nearly 1,000 patients were registered to receive treatment with ibrutinib in this indication. This is in line with NICE’s estimates that 700 adults per year would be eligible for treatment as a result of its guidance.</p><p>However, NHS England has further advised that it is more than willing to receive and review by the end of July, any further evidence that patients and clinicians wish to submit on this matter. The evidence will first be considered by NHS England’s Chemotherapy CRG, with advice and recommendations from this group then being submitted to the National Medical Director, Professor Steve Powis, for consideration.</p><p>During 2017/18, 1,193 Individual Funding Requests were considered by NHS England. An analysis of how may related to treatments for blood cancer has not been conducted.</p><p> </p> question first answered 26/06/2018 12:13:53
	creator	4286 label Biography information for Lord Mendelsohn
	publisher	25277 pref label House of Lords
	tabling member	4286 label Biography information for Lord Mendelsohn

767939

	human indexable
	published
	registered interest
	answer date	24/10/2017
	date	10/10/2017
	date tabled	10/10/2017
	ddp created	10/10/2017 21:29:37
	answering body	Department for Exiting the European Union
	question status	Tabled
	answering dept id	203
	answering dept short name	Exiting the European Union
	answering dept sort name	Exiting the European Union
	ddp modified	10/10/2017 21:37:48 23/10/2017 12:22:04
	hansard heading	Regulation
	house id	2
	identifier	HL1858
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	23/10/2017 11:50:07
	question text	To ask Her Majesty's Government how many EU-level regulatory bodies they anticipate will require the establishment of a new UK-level body as a result of the UK's departure from the EU and the conversion of EU law into UK law; and by what date they plan to have those bodies established.
	session	2017/19
	session number	1
	tabling member printed	Lord Mendelsohn
	title	House of Lords Tabled Parliamentary Question 2017/19 HL1858
	type	WrittenParliamentaryQuestion
	uin	HL1858
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction answer text <p>No decisions have yet been taken on our future relationship with the EU's regulatory bodies after exiting the EU. We are carefully considering a range of options and preparing for a number of negotiation outcomes.</p><p>Prior to any decisions on establishing new UK-level bodies, the Government will, however, always look to minimise disruption and costs, which will include considering alternative options. The European Union (Withdrawal) Bill makes clear that any decision on creating new agencies would require the approval of both Houses of Parliament under the affirmative procedure.</p><p>We will continue to plan for a range of scenarios and be ready to take any necessary steps to ensure that we are ready for exit day.</p><p> </p> question first answered 23/10/2017 11:50:07
	creator	4286 label Biography information for Lord Mendelsohn
	publisher	25277 pref label House of Lords
	tabling member	4286 label Biography information for Lord Mendelsohn

922990

	human indexable
	published
	registered interest
	answer date	26/06/2018
	date	12/06/2018
	date tabled	12/06/2018
	ddp created	12/06/2018 21:25:52
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	12/06/2018 21:35:47 26/06/2018 12:46:05
	hansard heading	Haematological Cancer
	house id	2
	identifier	HL8563
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	26/06/2018 12:13:53
	question text	To ask Her Majesty's Government how many Individual Funding Requests have been submitted to the NHS for the treatment of blood cancer; and of those, how many requests were (1) successful, and (2) unsuccessful.
	session	2017/19
	session number	1
	tabling member printed	Lord Mendelsohn
	title	House of Lords Tabled Parliamentary Question 2017/19 HL8563
	type	WrittenParliamentaryQuestion
	uin	HL8563
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction answer text <p>NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>In the case of NICE Technology Appraisal TA429 for ibrutinib in previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation, NICE issued the following statement on 8 June 2018:</p><p><strong> </strong>“Given the evidence that was considered by the NICE appraisal committee, we consider it reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment. Because unsuitability for retreatment is not defined in the guidance, we consider it appropriate for NHS England, as the commissioner, to take clinical advice in order to do so.”</p><p>NHS England took clinical advice in setting the specific treatment criteria linked to this appraisal and we are advised that the criteria were derived from the main study that had underpinned the NICE guidance and are consistent with guidance issued by the European Society for Medical Oncology last updated in June 2017. Between January 2017 and May 2018, nearly 1,000 patients were registered to receive treatment with ibrutinib in this indication. This is in line with NICE’s estimates that 700 adults per year would be eligible for treatment as a result of its guidance.</p><p>However, NHS England has further advised that it is more than willing to receive and review by the end of July, any further evidence that patients and clinicians wish to submit on this matter. The evidence will first be considered by NHS England’s Chemotherapy CRG, with advice and recommendations from this group then being submitted to the National Medical Director, Professor Steve Powis, for consideration.</p><p>During 2017/18, 1,193 Individual Funding Requests were considered by NHS England. An analysis of how may related to treatments for blood cancer has not been conducted.</p><p> </p> question first answered 26/06/2018 12:13:53
	creator	4286 label Biography information for Lord Mendelsohn
	publisher	25277 pref label House of Lords
	tabling member	4286 label Biography information for Lord Mendelsohn